dulanermin
Peptideexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2006 (NCT00400764)
Timeline
Indications
Mechanism of action
- TRAIL receptor-1AGONIST
TNFRSF10A agonist
Binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis.
TNFRSF10B agonist
Binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis.
- TRAIL receptor-1INHIBITOR
TNFRSF10A inhibitor
TNFRSF10B inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107846 ↗
Also known as
- amg 951
- apo-2l protein, human
- apo2l/trail
- circularly permuted trail protein, human
- datr protein, human
- dulanermin
- dulanermin
- dulanermin
- dulanermin
- recombinant human apo-2 ligand
- tnfsf10 protein, human
- trail protein, human
- tumor necrosis factor (ligand) superfamily, member 10 protein, human
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03083743 | Phase 3 | Oct 1, 2016 | Chinese Academy of Medical Sciences, Shanghai Gebaide Biotechnology Co., Ltd. |
| NCT00873756 | Phase 1 | May 1, 2009 | Genentech |
| NCT00671372 | Phase 1 | Jul 1, 2006 | Genentech |
| NCT00400764 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2006 | Amgen, Genentech |
| NCT00508625 | Phase 2 | Jun 1, 2006 | Amgen, Genentech |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 4 | 3 | 2 | 2006 |
| Amgen | For profit | 2 | 1 | 1 | 2006 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Shanghai Gebaide Biotechnology Co., Ltd. | Government | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1